362606-12-0

Basic information

• Product Name: C-ISOQUINOLIN-8-YL-METHYLAMINE
• Synonyms: C-ISOQUINOLIN-8-YL-METHYLAMINE;8-ISOQUINOLINEMETHANAMINE;Isoquinolin-8-yl-methylamine;(Isoquinolin-8-yl)methanamine dihydrochloride;(isoquinolin-8-yl)methanamine;8-(aMinoMethyl)isoquinoline
• CAS NO: 362606-12-0
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 158.2
• Product Categories: Building Blocks;Isoquinoline
• Mol File: 362606-12-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 330.8 °C at 760 mmHg
• Flash Point: 174.5 °C
• Appearance: /
• Density: 1.156 g/cm³
• Vapor Pressure: 0.000162mmHg at 25°C
• Refractive Index: 1.662
• CAS DataBase Reference: C-ISOQUINOLIN-8-YL-METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: C-ISOQUINOLIN-8-YL-METHYLAMINE(362606-12-0)
• EPA Substance Registry System: C-ISOQUINOLIN-8-YL-METHYLAMINE(362606-12-0)

Safety Data

• Hazardous Substances Data: 362606-12-0(Hazardous Substances Data)

Usage

General Description

C-ISOQUINOLIN-8-YL-METHYLAMINE is a chemical compound that contains an isoquinolin-8-yl group linked to a methylamine molecule. It is commonly used in pharmaceutical research and drug development, particularly in the synthesis of new drugs and potential therapeutic agents. The isoquinolin-8-yl group provides the compound with a rigid and aromatic structure, which is important for its biological activity. This chemical may have potential applications in the development of new medications for various medical conditions, and it is an important building block for the creation of novel drug candidates. Additionally, it may have uses in other fields, such as chemical biology, medicinal chemistry, and organic synthesis.

InChI:InChI=1/C10H10N2/c11-6-9-3-1-2-8-4-5-12-7-10(8)9/h1-5,7H,6,11H2

Upstream product

• 63927-22-0 8-bromo-isoquinoline 
• 362606-11-9 isoquinoline-8-carbonitrile 

Relevant articles and documents

AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein "R1", "RA-1", "R2", "R3", and "Het" are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.